Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to ...

We recently compiled a list of 11 Best Future Stocks to Buy Now. Arrowhead Pharmaceuticals, Inc. stands seventh on our list.

Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.

Ionis Pharmaceuticals Inc (IONS) reports robust revenue growth and strategic advancements, setting the stage for future ...

The opinion is based on positive data from the phase 3 Balance study, which showed a significant reduction of triglycerides ...

European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Months ...

European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Months ...

Sanofi will acquire rights to develop and commercialize the drug for $130 million upfront, with Visirna eligible for up to $265 million in milestone payments.

Q2 2025 Management View Brett P. Monia, CEO, stated the company "continued to build strong momentum across our business, highlighted by the excellent early commercial performance of our first ...

Ionis Pharmaceuticals IONS reported second-quarter 2025 adjusted earnings per share (EPS) of 86 cents, significantly beating the Zacks Consensus Estimate of 27 cents. In the year-ago period, the ...

Numerous severe thunderstorms are possible across North Dakota on Friday, continuing a recent pattern of dangerous weather.

A weather system could potentially impact over 500,000 people across the state, with tennis ball-sized hail and heavy rain forecast along with winds gusting up to 70 mph.